NSUN2 and pancreatic neoplasm: Multiple clinical studies have demonstrated that NSUN2 is significantly upregulated across various solid tumors and hematologic malignancies, including pancreatic cancer, acute myeloid leukemia (AML), osteosarcoma, colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), and gastric cancer (39, 53).